18F-FDG PET/CT对皮肌炎抗MDA5抗体及预后的预测价值n

来源 :中华核医学与分子影像杂志 | 被引量 : 0次 | 上传用户:misariza
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:分析抗黑色素瘤分化相关基因5(MDA5)抗体阳性皮肌炎患者的肌肉FDG代谢、肿瘤发生率以及肺间质性改变在n 18F-FDG PET/CT的影像特征及其鉴别抗MDA5抗体阳性皮肌炎的价值。n 方法:回顾性分析2016年6月至2019年7月在上海交通大学医学院附属仁济医院接受n 18F-FDG PET/CT检查的75例(34例抗MDA5抗体阳性,41例抗MDA5抗体阴性)皮肌炎患者[男21例、女54例,年龄(52.3±14.3)岁]和30名健康对照者[男10名、女20名,年龄(53.5±11.8)岁]的影像和临床资料,测定并计算肌肉SUVn max及肌肉SUVn max平均值(mSUVn max);统计皮肌炎患者合并肿瘤性病变的情况;测定皮肌炎合并间质性肺炎患者肺炎病灶的SUVn max。采用两独立样本n t检验、单因素方差分析、SNK检验和n χ2检验分析数据;行ROC曲线分析肌肉mSUVn max鉴别抗MDA5抗体阳性皮肌炎的诊断效能。n 结果:健康对照者、抗MDA5抗体阳性和抗MDA5抗体阴性皮肌炎患者的肌肉mSUVn max分别为0.39±0.05、0.66±0.21和0.87±0.29(n F=39.93, n P<0.001);皮肌炎患者的肌肉mSUVn max均高于健康对照者(n q值:6.76、12.63,均n P<0.001);抗MDA5抗体阴性患者高于抗MDA5抗体阳性患者(n q=5.79,n P<0.001)。ROC AUC为0.74,当肌肉mSUVn max取最佳阈值0.75时,在皮肌炎中鉴别出抗MDA5抗体阳性的准确性为74.7%(56/75)。抗MDA5抗体阴性患者中,恶性肿瘤6例(14.6%,6/41);抗MDA5抗体阳性患者中,无恶性肿瘤病例(0/34; n χ2=5.41,n P=0.020)。抗MDA5抗体阴性伴发间质性肺炎11例(26.8%, 11/41),抗MDA5抗体阳性伴发间质性肺炎33例(97.1%, 33/34; n χ2=37.81,n P<0.001);抗MDA5抗体阳性患者肺炎FDG代谢高于抗MDA5抗体阴性患者(SUVn max:3.65±1.83和2.38±1.27;n t=2.13,n P=0.039)。n 结论:抗MDA5抗体阳性皮肌炎患者的肌肉FDG代谢高于健康对照者,但低于抗MDA5抗体阴性患者。抗MDA5抗体阳性患者肿瘤性病变发生率低于抗MDA5抗体阴性患者。抗MDA5抗体阳性患者发生间质性肺炎的比例和严重程度均高于阴性患者。n 18F-FDG PET/CT对于鉴别抗MDA5抗体阳性皮肌炎具有一定价值。n “,”Objective:To assess the imaging characteristics of muscle FDG metabolism, tumor incidence, and pulmonary interstitial changes in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody positivity in n 18F-FDG PET/CT imaging, and the value of n 18F-FDG PET/CT in differentiating anti-MDA5 antibody positive dermatomyositis.n Methods:From June 2016 to July 2019, the PET/CT images of 75 patients with dermatomyositis (21 males, 54 females, age (52.3±14.3) years; 34 anti-MDA5 antibody positive and 41 anti-MDA5 antibody negative) and 30 healthy controls (10 males, 20 females; age (53.5±11.8) years) were retrospectively analyzed in Renji Hospital, School of Medicine, Shanghai Jiao Tong University. The SUVn max of muscle was measured and the mean of SUVn max (mSUVn max) was calculated. Statistics of patients with dermatomyositis complicated with neoplastic lesions and the SUVn max of pneumonia lesions in patients with dermatomyositis complicated with interstitial pneumonia was determined. Independent sample n t test, one-way analysis of variance, Student-Newman-Keuls (SNK) test and n χ2 test were used to analyze data. The ROC curve analysis was used to analyze the diagnostic efficacy of mSUVn max for the differential diagnosis of anti-MDA5 antibody positive dermatomyositis.n Results:The muscle mSUVn max of the control group, anti-MDA5 antibody positive and negative groups were 0.39±0.05, 0.66±0.21 and 0.87±0.29 (n F=39.93, n P<0.001), respectively. The muscle mSUVn max of dermatomyositis patients was increased compared with healthy controls (n q values: 6.76, 12.63, both n P<0.001), and the muscle mSUVn max of anti-MDA5 antibody negative was higher than positive (n q=5.79, n P<0.001). The AUC was 0.74, and the cut-off value of muscle mSUVn max was 0.75 with the accuracy of 74.7%(56/75). Of 41 patients with negative anti-MDA5 antibody, there were 6 (14.6%) had malignant tumor, while there was no malignant tumor in patients with positive anti-MDA5 antibody (0/34; n χ2=5.41, n P=0.020). There were 11 patients (26.8%, 11/41) with anti-MDA5 antibody negative dermatomyositis complicated with interstitial pneumonia and 33 patients (97.1%, 33/34) with anti-MDA5 antibody positive dermatomyositis complicated with interstitial pneumonia (n χ2=37.81, n P<0.001). FDG metabolism in anti-MDA5 antibody positive patients was higher than that in anti-MDA5 antibody negative patients (lesion SUVn max: 3.65±1.83 and 2.38±1.27; n t=2.13, n P=0.039).n Conclusions:The muscle FDG metabolism of anti-MDA5 antibody positive dermatomyositis patients is higher than that of healthy controls, but lower than that of anti-MDA5 antibody negative patients. The incidence of neoplastic lesions in patients with positive anti-MDA5 antibody is lower than that in patients with negative anti-MDA5 antibody. The proportion and severity of interstitial pneumonia are higher in patients with positive anti-MDA5 antibody than in those with negative anti-MDA5 antibody. n 18F-FDG PET/CT has certain value on identifying anti-MDA5 antibody positive dermatomyositis.n
其他文献
目的 了解在社区卫生综合改革背景下及“1+1+1”签约服务基础上社区居民分级诊疗和双向转诊的现状,分析社区居民分级诊疗和双向转诊行为的影响因素,为分级诊疗、双向转诊制度的完善提供依据,为实现便利化的分级诊疗打下坚实的基础.方法 采取分层整群随机抽样方法,抽取青浦区3个街镇社区卫生服务中心的社区患者进行问卷调查.共发放问卷800份,回收问卷744份,问卷回收率为93.00%.结果 就医行为调查结果显示,68.28%社区居民就医习惯首选社区医院;81.73%的研究对象表示认可社区首诊;70.97%社区居民选择
目的:探讨n 131I治疗前刺激性甲状腺球蛋白(psTg)水平对甲状腺乳头状癌(PTC)术后功能性残留淋巴结转移且无远处转移患者n 131I最佳治疗反应(ER)的预测价值。n 方法:回顾性纳入2011年3月至2015年6月间于郑州大学附属肿瘤医院行甲状腺双侧叶全切+淋巴结清扫术后首次行n 131I治疗时确诊为功能性残留淋巴结转移且无远处转移的PTC患者72例[男22例、女50例,年龄14~76(46.5±14.4)岁;血清甲状腺球蛋白抗体(TgAb)水平均正常]。根据
目的:探讨n 99Tcn m-焦膦酸盐(PYP)不同采集方法在心脏淀粉样变(CA)诊断与病理分型中的应用。n 方法:回顾性分析2018年12月至2019年12月间北京协和医院31例临床怀疑CA的患者资料,其中男22例、女9例,年龄21~81(57.2±13.4)岁。患者注射n 99Tcn m-PYP后不同时间行平面显像[早期显像(注射后1 h)、延迟显像(注射后2~3 h)]和断层显像(注射后1 h)。以临床诊断为标准,分别采用视觉评分法(≥2分为阳性)和半
目的:探讨n 125I粒子治疗食管鳞状细胞癌(简称鳞癌)颈部转移淋巴结放疗后复发的近期疗效影响因素。n 方法:回顾性分析2013年1月至2019年3月间于河北省人民医院行n 125I粒子植入的食管鳞癌颈部转移淋巴结放疗后复发的47例患者(男42例,女5例;年龄:47~77岁)资料。n 125I粒子治疗前后进行CT检查,术后3个月根据实体瘤疗效评价标准(RECIST)进行近期疗效评价,分为有效组[完全缓解(CR)+部分缓解(PR)]和无效组[病情稳定(SD)+病情进展(
前列腺癌是一种高度异质性疾病,目前治疗重点是识别与治疗预后不良的高危肿瘤,减少对惰性、低风险肿瘤的过度治疗。近年来,影像学在前列腺癌的探查、分期、治疗后评估和复发检测中的重要性逐渐增加。在不同的临床场景中,包括传统与功能检测在内的多种成像方式各有其优势与限制。该文概述目前应用于前列腺癌的影像学检测方法,从初期诊断到晚期转移性去势抵抗性前列腺癌,详细介绍了不同影像方法在上述临床场景中的应用价值。除了既定的影像学检查适应证,该文还强调了现行影像学检查的一些未来潜在应用。
目的:自动化合成Aln 18F-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-成纤维细胞激活蛋白抑制剂(FAPI)-04,并进行体内显像,评估其诊断肿瘤的效能。n 方法:利用All-in-one型自动合成模块合成Aln 18F-NOTA-FAPI-04,并进行质量分析;取3只正常BALB/c小鼠和3只4T1小鼠乳腺癌荷瘤小鼠进行PET/CT显像,观察体内Aln 18F-NOTA-FAPI-04分布情况;对1例肝细胞肝癌患者(男,51岁)进行Aln
期刊
期刊
目的:评价n 11C-胆碱PET/CT动态脑显像对海马硬化难治性颞叶癫n (HS-RTLE)致n 灶的定位诊断价值,并与n 18F-FDG、n 11C-氟马西尼(FMZ) PET/CT进行对比。n 方法:回顾性分析2017年3月至2020年6月间北部战区总医院经病理证实为海马硬化(HS)的62例患者[男39例、女23例,年龄(30.3±11.2)岁],术前均行多核素(n 18F-FDG、n 11C-FMZ、n 11C-
期刊